Prenatal Polycyclic Aromatic Hydrocarbon Exposure Leads to ...

1 downloads 7 Views 424KB Size Report
For permissions, please email: [email protected] ..... target mRNA gene/protein expression levels relative to 18sRNA/b-actin. The.

TOXICOLOGICAL SCIENCES 118(2), 625–634 (2010) doi:10.1093/toxsci/kfq304 Advance Access publication October 1, 2010

Prenatal Polycyclic Aromatic Hydrocarbon Exposure Leads to Behavioral Deficits and Downregulation of Receptor Tyrosine Kinase, MET Liu Sheng,* Xinxin Ding,† Marcus Ferguson,* Monique McCallister,* Raina Rhoades,* Mark Maguire,* Aramandla Ramesh,‡ Michael Aschner,§ Daniel Campbell,{ Pat Levitt,k and Darryl B. Hood*,1 *Department of Neuroscience and Pharmacology, Center for Molecular and Behavioral Neuroscience, Meharry Medical College, Nashville, Tennessee 37208; †Wadsworth Center, New York State Department of Health, Albany, New York 12201-2002; ‡Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, Tennessee 37208; §Departments of Pediatrics and Pharmacology, Center in Molecular Toxicology and Kennedy Center for Research on Human Development, Vanderbilt University School of Medicine, Nashville, Tennessee 37212; {Department of Psychiatry and the Behavioral Sciences, Zilkha Neurogenetic Institute, Center for Genomic Psychiatry, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089; and kDepartment of Cell and Neurobiology, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, California 90089 1

To whom correspondence should be addressed. Fax: (615) 327-6632. E-mail: [email protected] Received June 29, 2010; accepted September 8, 2010

Gene by environment interactions (G 3 E) are thought to underlie neurodevelopmental disorder, etiology, neurodegenerative disorders, including the multiple forms of autism spectrum disorder. However, there is limited biological information, indicating an interaction between specific genes and environmental components. The present study focuses on a major component of airborne pollutants, polycyclic aromatic hydrocarbons (PAHs), such as benzo(a)pyrene [B(a)P], which negatively impacts cognitive development in children who have been exposed in utero. In our study, prenatal exposure of Cprlox/lox timed-pregnant dams to B(a)P (0, 150, 300, and 600 mg/kg body weight via oral gavage) on embryonic day (E14–E17) consistent with our susceptibility-exposure paradigm was combined with the analysis of a replicated autism risk gene, the receptor tyrosine kinase, Met. The results demonstrate a dose-dependent increase in B(a)P metabolite generation in B(a)P-exposed Cprlox/lox offspring. Additionally, a sustained persistence of hydroxy metabolites during the onset of synapse formation was noted, corresponding to the peak of Met expression. Prenatal B(a)P exposure also downregulated Met RNA and protein levels and dysregulated normal temporal patterns of expression during synaptogenesis. Consistent with these data, transcriptional cell–based assays demonstrated that B(a)P exposure directly reduces human MET promoter activity. Furthermore, a functional readout of in utero B(a)P exposure showed a robust reduction in novel object discrimination in B(a)P-exposed Cprlox/lox offspring. These results confirm the notion that common pollutants, such as the PAH B(a)P, can have a direct negative impact on the regulated developmental expression of an autism risk gene with associated negative behavioral learning and memory outcomes. Key Words: gene 3 environment interaction; autism spectrum disorders; polycyclic aromatic hydrocarbon; benzo(a)pyrene; susceptibility-exposure paradigm; novel object discrimination behavioral task; in utero exposures; behavioral neurotoxicity.

Although hypotheses that espouse gene by environment (G 3 E) etiologies for neurodevelopmental disorders are well recognized (Wang et al., 2010), genetic and environmental factors are typically studied separately. For example, replicated genes recently have been identified that increase the risk for autism spectrum disorder (ASD), a highly heterogeneous clinical syndrome in which variation in endophenotypes or disorder expression is likely due to G 3 E interactions. There is a strong rationale for examining common air pollutants as contributors to putative G 3 E effects in neurodevelopmental disorders. First, the human health consequences of prenatal exposure to benzo(a)pyrene [B(a)P], a polycyclic aromatic hydrocarbon (PAH), are substantial, with demonstrated associations to reductions in the mental development index and IQ in the high-exposure cohort of 3- and 5-year-old children exposed in utero to PAHs (Perera et al., 2006, 2009). There is a range of B(a)P concentrations to which pregnant women are exposed, which suggests that the cognitive impact on their fetuses is due to a more complex mechanism than the well-described aryl hydrocarbon receptor signaling (Nebert et al., 2000). Brain levels of PAHs in B(a)P-exposed children cannot be monitored, thus requiring more mechanistic studies utilizing mouse models to define developmental neurobiological effects resulting from exposure to PAHs during key periods of circuit formation in the brain. Moreover, this strategy provides opportunities to directly examine prenatal PAH impact on recognized candidate genes for specific neurodevelopmental disorders. The objective of the present study was to characterize the interaction between in utero exposure to B(a)P and the gene encoding the MET receptor tyrosine kinase, a replicated ASD risk gene (Jackson et al., 2009; Sousa et al., 2009) that mediates neuronal process growth and synapse formation (Akita et al., 2008; Gutierrez et al., 2004; Nakano et al., 2007). Our own evaluation of linkage peaks extended beyond genes

 The Author 2010. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: [email protected]



with selective brain expression to consider the complex medical conditions observed in autism patients. Over the years, analytical applications in developmental biology and genetics have converged to implicate the gene encoding the MET receptor tyrosine kinase (OMIM 164860; GenBank accession NM_000245; chromosome 7q31) as an autism candidate gene. Recent studies by the Levitt group and others have revealed that MET also contributes to the development of the cerebral cortex (Powell et al., 2001, 2003), which exhibits developmental disruptions in autism (Palmen et al., 2004) and in animal model susceptibility paradigms of developmental environmental contaminant exposure (Hood et al., 2006; McCallister et al., 2008). The relationship between genetic risk and phenotypes characteristic of ASDs lies in the patterns of gene expression and the function of the encoded proteins in specific circuits during development. Based on recent biological studies, we have suggested that MET receptor activation influences the development and maturation of these circuits (Levitt and Campbell, 2009). This neurodevelopmental role is consistent with recent genetic findings that indicate a significant association of the MET promoter variant rs1858830 C allele with ASD risk in three independent cohorts (Campbell et al., 2006, 2008). Furthermore, MET transcript and MET protein have been found to be significantly decreased in postmortem brains of individuals with ASD (Campbell et al., 2007). Our focus on MET receptor tyrosine kinase is justified on the basis of relevant human studies, and it is likely only one of the number of targets for B(a)P. Met expression in the mouse coincides with the onset and peak of synapse formation in the neocortex during the first two postnatal weeks (Judson et al., 2009). In the human, this corresponds to an exposure period during the second and third trimester and expression analysis in third trimester through the first postnatal year (Levitt, 2003). Genetically induced hypomorphic Met signaling alters neuronal differentiation, and stimulation of the receptor by its sole ligand, hepatocyte growth factor, enhances the expression of NMDA receptor subunits (Tyndall and Walikonis, 2006). PAHs have been shown to alter developmental processes involving glutamatergic signaling (McCallister et al., 2008, Wormley et al., 2004). Here, we used a mouse model of in utero exposure, similar in design to those of other rodents, with a focus on Met in order to establish parameters for the direct examination of G 3 E effects that may be relevant to a specific subset of environmental-induced ASD-like symptomology. Our wild-type (WT) Cpr mouse model is but one of the many such models. Mutant P-450 oxidoreductase (POR) alleles have been found to be associated with congenital deficiencies in steroidogenesis/homeostasis and/or with the Antley Bixler Syndrome, characterized by skeletal malformation and reproductive defects (Fluck et al., 2004; Fukami et al., 2005). Other known phenotypes of the Cpr-low mouse, such as lower cholesterol levels and reduced embryonic survival, as well as phenotypes yet to be identified, are also anticipated to occur in

human patients. The results from our study demonstrate the functional impact of in utero B(a)P exposure as tested by examining the impact on behavior that is mediated by maturing cortical circuits.

MATERIALS AND METHODS The WT mouse utilized and characterized in the present study is the Cytochrome p450 reductase or Cprlox/lox mouse. Nested in this study is an obligatory characterization of this WT Cprlox/lox mouse for B(a)P disposition and metabolite bioavailability against the background C57BL/6J strain. The usefulness of this model and its relevance to human POR (POR, for P450 oxidoreductase) deficiency has been widely reported and is supported by the occurrence of substantial interindividual variations in levels of Cpr expression in human tissues (Wortham et al., 2007). Utilization of the Cpr mouse model will be important for future studies in which a Cpr-low activity (i.e., brain-Cpr-null) phenotype has been identified (Gu et al., 2007). This brain-Cpr-null phenotype does not possess the ability to produce B(a)P metabolites from the parent compound due to the reduced expression of POR, thus allowing determinations of the extent to which oxidative metabolites of B(a)P contribute to any observed developmental and behavioral defects. Power analysis was used to determine the appropriate number of Cprlox/lox offspring required; the number of litters was used as the statistical unit. For the present analysis, four cohorts of four experimental groups were utilized: (1) a control Cprlox/lox group (vehicle exposed with peanut oil); (2) a 150 lg/kg body weight (BW) B(a)P-exposed Cprlox/lox group; (3) a 300 lg/kg BW B(a)Pexposed Cprlox/lox group; and (4) a 600 lg/kg BW B(a)P-exposed Cprlox/lox group. All experiments utilized groups 1 through 3 except for the semiquantitative PCR experiments. Cprlox/lox offspring mice from control (n ¼ 4–5 litters) and B(a)P-exposed (n ¼ 4–5 litters) dams were used to collect the molecular and behavioral data. For each repetition, it was estimated that the variance between measures from litters would be 10% of the mean response. Because the litter was the statistical unit, three replicates for metabolite disposition and molecular and behavioral studies were deemed to be sufficient because the power analysis established that three successful experiments in each Cprlox/lox cohort would be required to detect a 20% change in any of the experimental end points with 80% power and a type I error rate of 5%. This estimate held true as we were able to detect differences ± the variance in the effect of B(a)P exposure on Cprlox/lox offspring relative to control offspring for metabolite disposition, molecular and behavioral studies. Animal husbandry and B(a)P treatment using the susceptibility-exposure paradigm. Experiments were approved by the Institutional Animal Care and Use Committee of Meharry Medical College and were performed according to Guidelines for Animal Experimentation as set forth by the National Institutes of Health and both institutions. Cprlox/lox mice were obtained from the Wadsworth Center, New York State Department of Health, Albany, New York. Cprlox/lox mating pairs were maintained in our AAALAC accredited animal care facility and are propagated to maintain our female F1 generation colony to ~30 breeders. Typically, a male of the appropriate genotype was placed with a pair of females (3–4 months old) of the appropriate genotype overnight, 13 per week. During this period, females received a nutritional high-fat diet supplement (Lovemash Bioserv, Frenchtown, NJ) that has proven helpful in stabilizing litter size. A combination of a positive sperm plug, positive vaginal smear identification, and the monitoring of weight gain ensured the identification of pregnant Cprlox/lox dams by E11. Subsequently, four to five timed-pregnant Cprlox/lox females per group were moved into a 3-day holding protocol prior to B(a)P exposure. On embryonic day (E14–E17), Cprlox/lox dams were exposed to B(a)P (150, 300, and 600 lg/kg BW) by oral gavage. The proper controls for the B(a)P (in peanut oil) gavage exposures of Cprlox/lox timed-pregnant dams were, in fact,

B(a)P-INDUCED MODULATION OF MET EXPRESSION conducted. These controls consisted of Cprlox/lox timed-pregnant dams that were sham exposed to an equivalent volume of peanut oil. Generally, Cprlox/lox dams gave birth on E20. Following delivery, Cprlox/lox dams were supplemented with Supreme Mini-Treats (Bioserv, Frenchtown, NJ) to reduce cannibalism. Cprlox/lox litters were maintained in a controlled environment with a temperature set at 21 ± 2C and a relative humidity of 50 ± 10% with a 12/12 h-light/dark cycle. Cprlox/lox dams were fed commercial food (Rat Chow 5012; Purina Mills, St Louis, MO). Water and food were available ad libitum. The numbers of pups within the control and treatment groups were not standardized on the day of birth due to the need to remove pups from litters to conduct metabolite disposition and expression profiling studies. Litter size and pup weights were recorded. On various postnatal days (PND), pups were removed from litters and anesthetized with CO2. For PND 0–5, whole brains were exposed, removed, and frozen in liquid nitrogen until the homogenates were prepared for B(a)P metabolite disposition and messenger RNA (mRNA) and protein expression profiling analysis. For PND 7–15, left and/or right cerebral cortices were exposed, removed, and frozen in liquid nitrogen until the homogenates were prepared for B(a)P metabolite disposition and mRNA and protein expression profiling analysis. Additionally, at autopsy, a 0.25- to 0.35-cm piece of the tail was collected for genotyping. Each data point for metabolite disposition and expression profiling comprised 100–200 mg portions of the whole brain (for P0–P5 time points) or 100–200 mg portions of the left or right cerebral cortex (for P7–P15 time points) from at least four to five different litters within the experimental groups. B(a)P metabolite disposition and analysis from whole-brain or cerebral cortex tissue. Whole-brain tissue or left-right cerebral cortices from control and B(a)P-exposed Cprlox/lox offspring were processed for bioavailable levels of B(a)P metabolites by liquid-liquid extraction and reverse phase highperformance liquid chromatography methods as described previously in Ramesh et al. (2001). Cell transcription assays. The cell-based transcriptional assays were performed as described previously (Campbell et al., 2006) using a 762-bp fragment of the MET promoter, which encompasses the rs1858830 locus. Following the manufacturer’s protocols, the human MET amplicon was cloned into the pSTBlue-1 AccepTor vector (Novagen, Madison, WI), which was then directionally subcloned into the pGL4.10 (luc2) luciferase reporter vector (Promega, Madison, WI). Human embryonic kidney (HEK) cell lines (ATCC) were also used. For exposure experiments, 2 lg of luciferase reporter construct were cotransfected with 80 ng of pRL-CMV (Renilla luciferase fused to the strong cytomegalovirus promoter; Promega) using the Amaxa Nucleofector system (Amaxa, Gaithersburg, MD). B(a)P (98% pure; Sigma) was resuspended in 100% dimethyl sulfoxide (DMSO) at a concentration of 2mM. Serial dilutions were prepared in 100% DMSO. Twenty-four hours after transfection, cells were exposed to a range of 100–1000nM B(a)P or DMSO vehicle (0.05%) in Dulbecco’s Modified Eagle’s Medium growth medium. Luciferase assays were conducted using the Dual-Glo Luciferase Assay Kit (Promega) according to the manufacturer’s protocol. Each transfection was represented by six luminescence readings for both firefly and Renilla luciferase. The average luminescence reading from the mock-transfected negative control was used for the background and was subtracted from each well. The ratio of experimental (firefly) to control (Renilla) luciferase was calculated, and the six repeated ratios of each condition were averaged to give a single experimental/control ratio for each transfection. The experimental/control ratio of each MET promoter-containing construct, in nonexposed and chemical-exposed samples, was calculated. Data are expressed as the fold induction over promoter-less vector. Each transfection was considered a separate sample, and each condition was repeated six times (n ¼ 6). ANOVA followed by the Dunnett’s t-test was used to compare each concentration of B(a)P to the nontoxicant control. RT-PCR and Western analysis for mRNA/protein content of Met in brain tissue. To detect B(a)P-induced temporal modulation of Met mRNA and protein expression in control and B(a)P-exposed Cprlox/lox offspring, semiquantitative RT-PCR and Western blot analyses were used. Both


complementary DNA synthesis and RT-PCR amplification were produced in one step using Promega’s Access RT-PCR System; the sequences of designed primers and the final concentrations of reagents in the PCRs system were as previously indicated (McCallister et al., 2008). Target gene mRNA expression is presented as the relative ratio between the intensity of the target-specific band to that of the 18sRNA band. For protein evaluation, aliquots (50–100 mg) of the pooled littermate Cprlox/lox offspring cerebral cortices were used. Samples were lysed by homogenization in ice-cold buffer containing 50mM (4-(2hydroxyethyl)-1-piperazineethanesulfonic acid) (pH 7.4), 150mM NaCl, 20mM EDTA, 100lM NaF, 10mM Na3VO4, 1mM phenylmethylsulfonyl fluoride, 1mM leupeptin, 20 lg/ml aprotinin, and 1% Nonidet P-40. The protein content of the supernatants was determined using Bio-Rad protein assay reagent. Equal amounts of protein were separated on 10% SDS-polyacrylamide gels, transferred to nitrocellulose membranes, and Met was detected with specific antibodies. After incubation with mouse anti-Met primary antibody (Santa Cruz #8057), the nitrocellulose membranes were incubated with donkey antimouse peroxidase–conjugated secondary antibody. Proteins were visualized with the Amersham enhanced chemiluminescence system. Statistical analysis of developmental expression profiles (mRNA and protein). The values for Met mRNA and protein are reported as means ± SEM. A two-way ANOVA was used for the determination of statistical differences between control and B(a)P-exposed Cprlox/lox offspring groups in target mRNA gene/protein expression levels relative to 18sRNA/b-actin. The 18s was used as an internal standard for the RT-PCR analysis because this gene is not modulated as a result of B(a)P exposure. The 18s comprises up to 80% of a total RNA sample; thus, when the concentration of a total RNA sample is determined from spectrophotometric readings, the sample is essentially already normalized to the amount of rRNA it contains. rRNAs also are transcribed by a polymerase distinct from that of mRNAs, which may result in a different pattern of regulatory expression. The 18s rRNAs have been found to be uniform in all rodent tissues tested, including the liver, brain, thymus, heart, lung, spleen, testes, ovary, kidney, and in the embryo. Therefore, the choice of a housekeeping gene in this neurotoxicity study is based on empirical determinations regarding the effect of the toxicant on the system under examination. All pairwise multiple comparisons were performed using the Student-Newman-Keuls method. The criterion for statistical significance was p < 0.05 in all cases. Novel object discrimination. On P40, each mouse underwent one 30-min habituation session in a square activity chamber (43.2 3 43.2 cm; Med Associates, St Albans, VT). The automated activity chamber monitored the horizontal and vertical movement of the mouse by quantifying the photobeam disruption. Following this habituation, the mouse was returned to its home cage for 24 h, after which each animal underwent four habituation and testing sessions, each 15-min long, separated by 15-min intervals. In the first session, the mouse was allowed to habituate to the empty activity chamber for 30 min. In session 2, the animal was allowed to familiarize itself with two objects (familiar) placed in the rear chamber for 6 min. In session 3, the mouse was again placed in the activity chamber with the same arrangement of objects. Finally, in session 4, the session that tested response to novelty, one of the familiar objects from the previous session was replaced with a novel object for 6 min. Both the presentation and position of objects were alternated as a control. Analysis of responses to novelty in control and B(a)P-exposed Cprlox/lox offspring. Using open field activity software (Med Associates), activity in the chamber was measured. This software allows for post hoc definition of zones of interest. A zone of any size can be defined by selecting grid squares of photobeam intersections. With the open field activity interface, a small zone (5 3 5 photobeam grid) and a larger zone (6 3 6 photobeam grid) were designated around each object. The software collected and documented the total activity, number of entries into each zone (object approaches), and the time spent in each zone. Simultaneously, time spent with the objects was recorded using a stopwatch by an experimenter blinded to the identity of the experimental groups. Observational time included only that time during which



the animal was in close proximity (within 2 cm) or actively touching or sniffing the object. The novelty index was calculated using the formula NI ¼ (n  f)/ (n þ f), where n is the time with the novel object and f is the time with the familiar object. This index ranges from 1 to 1, with a 1 signifying complete preference for the familiar object, 0 signifying no preference, and 1 signifying complete preference for the novel object. Statistical evaluations were made using ANOVA and planned comparisons. An a level of 0.05 was considered significant for all statistical tests employed.


The Cprlox/lox mouse, a transgenic mouse strain generated for the conditional deletion of the NADPH-cytochrome P450 reductase (Cpr) gene, is essentially identical to the WT mouse, as the targeted insertion of the two loxP sites into the Cpr locus does not cause any effects on Cpr gene expression (Wu et al., 2003). The mouse, originally produced on a mixed C57BL/6 and 129/Sv background, has been backcrossed to the C57BL/6 strain for over 10 generations. As mentioned in the ‘‘Materials and Methods’’ section, the Cprlox/lox mouse is the WT control strain for future studies that will utilize tissue-specific Cpr-null mouse models, such as brain-Cpr-null (Conroy et al., 2010) and liver-Cpr-null models (Gu et al., 2003). Using Cprlox/lox mice in these studies, an analysis of live birth indices revealed no significant differences in the number of mouse pups born per litter between control Cprlox/lox dams and B(a)P-exposed Cprlox/lox dams (150, 300, and 600 lg/kg BW). A hallmark of the susceptibility-exposure paradigm is that the B(a)P exposure is restricted to a time window (E14–E17) that occurs well after implantation on E12 so as not to adversely affect fetus’ on the uterine horn. The live birth index for control Cprlox/lox dams was 5.22 ± 0.88 compared with 6.5 ± 0.69 for B(a)P-exposed Cprlox/lox dams (p ¼ 0.255). These normal parameters are consistent with previous reports from our group (Brown et al., 2007; Hood et al., 2000; McCallister et al., 2008) using rat models. During the prenatal exposure and subsequent preweaning periods, there were no identifiable B(a)P-related effects on conventional reproductive indices of toxicity. Additionally, there were no convulsions, tremors, or abnormal movements noted in any of the dams or offspring in control or B(a)P-exposed litters. Figure 1A provides data demonstrating the similarity of POR activity as assessed by the distribution of total B(a)P metabolites in the C57BL/6 timed-pregnant dam on PND 3 exposed to 600 lg/kg BW B(a)P from E14–E17. Inspection of Figure 1A reveals that on PND 3, the 4,5 diol groups of B(a)P metabolites comprise ~80% of the total metabolite distribution in C57BL/6 dams that were exposed to B(a)P from E14–E17. Comparatively, the disposition in Cprlox/lox offspring (PND 3) that were exposed in utero to 600 lg/kg BW B(a)P (Fig. 1B) comprise ~80% of the total metabolite distribution in these B(a)P-exposed Cprlox/lox offspring. The individual metabolites present in the B(a)P-exposed C57BL dams and Cprlox/lox offspring included the 4,5-,7,8-,9,10-diols, 3,6, and 6, 12-diones

and 3-OH and 9-OH B(a)P metabolites. Collectively, these data provide sufficient evidence to conclude that the POR are functioning at comparable rates in the WT strain of our mouse model as compared with the background C57BL strain. Figure 1B shows the dose-dependent accumulation (150, 300, or 600 lg/kg BW) of total B(a)P metabolites in neocortex during the critical postnatal period when synapses are first formed in B(a)P-exposed Cprlox/lox offspring. Data are shown for total neocortical B(a)P metabolite concentrations derived from Cprlox/lox offspring on PND 3, 5, 10, 15, and 20. On PND 3, a clear dose-response for B(a)P accumulation in neocortex is evident and indicative of an active phase 1 biotransformation pathway in our Cprlox/lox mouse model. Given the results of these disposition studies, it is important to emphasize here that the neocortical tissue burden of metabolites resulting from a 600 lg/kg oral exposure is less than the dietary intake of B(a)P by humans. This mean dietary intake of B(a)P by humans is 2–500 ng/day (Lioy et al., 1988) which translates to 200–7000 lg/kg/day for a healthy 70 kg individual. A comparison of Met transcript expression in the cerebral cortex at the onset (birth) through the most rapid production phase (PND 7) of synapses in control Cprlox/lox and B(a)Pexposed Cprlox/lox offspring is shown in Figure 2. Although there are no differences in Met expression at birth for any exposure dose, a statistically significant reduction in Met transcript is observed from PND 1 through 7 at the middle (300 lg/kg BW) and high (600 lg/kg BW) B(a)P doses used in the study. The results suggest that B(a)P exposure can reduce Met gene transcription directly. In order to corroborate the fact that B(a)P exposure alone is sufficient to alter MET expression, in vitro cell-based transcription assays were performed as described previously using the 762-bp fragment of the MET promoter variant rs1858830 locus allele, ‘‘C’’ or ‘‘G’’. HEK cells were transfected with the luciferase reporter constructs containing 762 bp of the MET promoter including either the ‘‘C’’ or ‘‘G’’ allele at the rs1858830 variant locus. Twenty-four hours after transfection, the cells were exposed for an additional 24 h to concentrations of B(a)P as indicated in Figure 3. These data clearly demonstrate a greater than fivefold significant decrease in MET transcription as a function of B(a)P exposure concentration. The data also illustrate the utility of luciferase assays to quantify the relative levels of MET promoter-driven transcription in our model. Although 500nM was not the highest concentration used in the study, from an environmental exposure standpoint, this amount represents an environmentally relevant concentration for B(a)P. These findings support the semiquantitative PCR results which demonstrate the B(a)P-induced downregulation of temporal, developmental MET mRNA expression as shown in Figure 2. The functional translation of altered gene transcription requires a concomitant reduction in protein accumulation. We characterized Met protein expression over a more extensive postnatal period (PND 1 through 14) following in utero



(E14–E17) exposure to B(a)P. The results demonstrate a robust2 dose-response effect in the B(a)P-induced disruption of temporal Met protein expression in the cerebral cortex as shown in Figure 4. Met normally is expressed at modest levels at birth, followed by a dramatic increase that coincides with the onset of rapid synapse formation (Judson et al., 2009). This increase is followed by a normal decrease by the third postnatal week. This temporal pattern was recapitulated here in the control Cprlox/lox offspring mice. The developmental expression profile of Met in B(a)P-exposed Cprlox/lox offspring (middle panel, 150 lg/kg BW) showed that Met developmental expression is at peak levels on PND 5, a full 5 days prior to the normal maximal peak level measured here at PND 10 in control Cprlox/lox offspring mice. Thus, there is a statistically significant reduction in Met expression at PND 10 in the B(a)P-exposed offspring mice compared with control offspring mice. By PND 15, Met expression in B(a)P-exposed Cprlox/lox offspring was reduced to very low levels, which is normal at this age. At the highest dose (300 lg/kg BW B(a)P) analyzed for impact on Met protein expression, there were statistically significant reductions in Met expression in mice at every age of examination. The normal increases in Met expression were evident at P5 and P10, but reached only ~25% of the levels found in control mice. These data demonstrate that exposure to B(a)P during a restricted period of cortical development in utero is sufficient to cause long-term alterations in both the developmental pattern and levels of expression of Met in the cerebral cortex. Although we have previously shown that in utero B(a)P exposure in rats can alter a number of key gluatmatergic signaling proteins and cause the consequent disruption of cortical neuronal activity and function, we sought to assess a behavioral parameter that might be altered due to the molecular disruptions in the cerebral cortices of mice described in the present study. The two-choice novel object discrimination (Silvers et al., 2007) was used to measure any B(a)P-induced reductions in novelty discrimination. In order to test for the ability to discriminate between a novel and a familiar object, the mouse

FIG. 1. B(a)P metabolite disposition during postnatal brain/cortical development. (A) Distribution of metabolite types in B(a)P-exposed C57BL/6 timed-pregnant dams. C57BL timed-pregnant dams received 600 lg B(a)P/kg BW via oral gavage on E14–E17. Neocortical tissue was retrieved from B(a)Pexposed C57BL dam on PND 3 and the distribution of the individual B(a)P metabolites was determined by high-performance liquid chromatography (HPLC) as outlined in Ramesh et al. (2001). Values represent mean ± SEM. The asterisk denotes statistical significance (p < 0.001) for different metabolite concentrations as compared with the 4,5-diol metabolite. (B) Distribution of metabolite types in B(a)P-exposed Cprlox/lox offspring demonstrating comparable POR activity in brain tissue. Timed-pregnant Cprlox/lox dams received 600 lg B(a)P/kg BW via oral gavage on E14–E17. Neocortical tissue was retrieved from B(a)P-exposed Cprlox/lox offspring on PND 3, and the distribution of the individual B(a)P metabolites was determined by HPLC as

outlined in Ramesh et al. (2001). Values represent mean ± SEM. The asterisk denotes statistical significance (p < 0.001) for different metabolite concentrations as compared with the 4,5-diol metabolite. (C) Dose-dependent accumulation of total neocortical B(a)P metabolites during the critical postnatal period when synapses are first formed in B(a)P-exposed Cprlox/lox offspring. Cprlox/lox offspring dosed in utero with either 150, 300, or 600 lg/kg BW were sacrificed on the indicated postnatal day, and brain tissue was frozen in liquid nitrogen subsequent to genotyping on PND 20. Offspring pups that were identified as carrying the allele Cprlox/lox were pooled, extracted, and the B(a)P metabolite concentrations was determined by HPLC as outlined in Ramesh et al. (2001). Shown are total metabolite concentrations measured in B(a)P-exposed Cprlox/lox offspring for the three B(a)P doses. Values represent mean ± SEM. Due to the limited volume of neocortical tissue present on PND 3 and 5, whole-brain tissue was used for these time points. The asterisk denotes statistical significance at p < 0.05.



FIG. 2. Analysis of Met mRNA in the cerebral cortex of B(a)P-exposed Cprlox/lox offspring. The top panel shows the results of electrophoresis of PCR products from PND 0, 1, 3, 5, and 7. The upper band is MET, and the lower band is 18sRNA (internal standard). The bottom panel shows the densitometric quantitation of the bands. There is a statistically significant dose-dependent reduction in the levels of cortical Met mRNA expression, depicted by the relative ratio between the intensity of the MET band and that of the 18sRNA band. The data are shown as mean ± SEM from three separate experiments; p < 0.05. M is the marker; a ¼ Control Cprlox/lox offspring (white bar); b ¼ 150 (black bar); c ¼ 300 (gray bar); d ¼ 600 (white-gray bar) lg/kg BW B(a)Pexposed Cprlox/lox offspring.

first attends to two identical familiar objects. Upon replacement of one of the familiar objects with a novel object, the animal should display preferential behavior toward the novel object. This generally occurs if the mouse can recognize that the object is novel. It is readily apparent in Figure 5 that each control Cprlox/lox offspring mouse tested spent more time with the novel than the familiar object, thereby producing a positive mean novelty discrimination index of 0.54 ± 0.13. Zones of two sizes (novel and familiar object; see Fig. 5) were quantitated around the novel and familiar objects in order to compare the observational data. An analysis of variance

FIG. 4. Analysis of Met protein expression in the cerebral cortex following in utero B(a)P exposure. The upper panel shows a representative experiment. The upper band is MET, and the lower band is the b-actin internal control (lanes 1–4). Control Cprlox/lox offspring; MET expression on PND 0, lane1; PND 5, lane 2; PND 10, lane 3; and PND 15, lane 4 (lanes 5–8) 150 lg/kg BW B(a)P-exposed Cprlox/lox offspring; PND 0, lane 5, PND 5, lane 6; PND 10, lane 7; and PND 15, lane 8 (lanes 9–12) 300 lg/kg BW B(a)P-exposed Cprlox/lox offspring; PND 0, lane 9; PND 5, lane 10; PND 10, lane 11; and PND 15 lane 12. There is an apparent dose-dependent decrease in Met protein detection, characterized by a premature peak at P5 in B(a)P-exposed Cprlox/lox offspring as compared with control Cprlox/lox offspring (P10). This was confirmed using semiquantitative analysis. The lower panel displays the histogram of the densitometric quantitation of the relative expression of Met to an internal b-actin internal control. *p < 0.05 relative to control in the 150 and 300 lg/kg BW B(a)P-exposed Cprlox/lox offspring.

revealed no significant differences between the five control Cprlox/lox offspring (observational, small zone, and large zone) with regard to novelty index data. However, for the five B(a)Pexposed Cprlox/lox offspring tested, significantly less time was spent with the novel than the familiar object as compared with controls, thereby producing a negative mean novelty discrimination index score of 0.26 ± 0.07 (p < 0.05 for the 150 lg/kg BW group). For the five B(a)P-exposed Cprlox/lox offspring in the 300 lg/kg BW group, the statistical significance of the deficit in response to novelty was even greater at 0.23 ± 0.10. Post hoc analysis with the Bonferroni test revealed the significance at p < 0.01.

DISCUSSION FIG. 3. Analysis of B(a)P exposure on human MET promoter activity in HEK cells. Twenty-four hours of exposure to different concentrations of B(a)P results in a statistically significant reduction in transcriptional activity from the human MET promoter. Transcriptional efficiency was measured by luciferase assay following transfection of a construct that drives a luciferase reporter with a 762-bp fragment of the MET promoter. *p < 0.05 by ANOVA followed by the Dunnett’s t-test. Shown is the mean ± SEM. of four independent determinations.

The present study establishes the validity of using genetically tractable mouse models (including the Cprlox/lox model) to explore G 3 E influences on molecular, structural, and functional brain development. Going forward, many of the Cpr phenotypes that we plan to exploit have already been identified including the Cpr-low mouse that exhibits a degree of infertility and altered steroid homeostasis (Wu et al., 2007)


FIG. 5. Analysis of the response to novelty. Prenatal B(a)P exposure induces a robust behavioral deficit in novel object discrimination compared with control Cprlox/lox offspring. Control and B(a)P-exposed Cprlox/lox offspring mice (n ¼ 5 per group) were acclimated and tested as described in the ‘‘Materials and Methods’’ section. Zones of two sizes (novel and familiar objects) were quantitated around the novel and familiar objects in order to compare the observational data. Control Cprlox/lox offspring mice spent more time with the novel than the familiar object, which produced a positive mean novelty discrimination index of 0.54 ± 0.13 (SEM) for control mice. Testing of B(a)P-exposed Cprlox/lox offspring revealed that significantly less time was spent with the novel than the familiar object as compared with controls, producing a negative mean novelty discrimination index score of 0.26 ± 0.07, p < 0.05 for the 150 lg/kg BW group. For the B(a)P-exposed Cprlox/lox offspring in the 300 lg/kg BW group, the statistical significance of the deficit in response to novelty was even greater, 0.230 ± 0.10. Post hoc analysis with the Bonferroni test revealed the significance at p < 0.01.

are known to occur at appreciable frequencies in human patients (Arlt et al., 2004; Fluck et al., 2004; Fukami et al., 2005, 2006; Huang et al., 2005). The results from the present study demonstrate that the transcription and developmental expression patterns of a replicated ASD risk gene, MET, are highly sensitive to a common PAH pollutant. In utero exposure to B(a)P produces an oxidative milieu of B(a)P metabolites in offspring during a key postnatal period of synapse development, providing evidence that environmental exposure creates a sustained cerebral cortical burden that likely contributes to an increased oxidative load. Oxidative stressors in the form of metabolites would be expected to negatively impact gene expression (Kerzee and Ramos, 2000) and, more specifically, receptor tyrosine kinase function, including Met (Li et al., 2007). These data suggest that B(a)P-induced exposure would impact the expression of key neurodevelopmental genes, including Met. Additionally, the predominance of the 3-OH and 9-OH metabolites places a sustained burden in the brain because of the potential for further oxidization to form B(a)P quinones (Brown et al., 2007; Hood et al., 2000; McCallister et al., 2008), which undergo redox cycling to generate reactive oxygen species (Bolton et al., 2000; Kerzee and Ramos, 2000).


The compelling rationale for the receptor tyrosine kinase, MET, as a viable target for gene 3 environment interactions during critical periods of development is based on a recently reported study on ASD (Morrow et al., 2008). The results from the current study have offered valuable data, clarifying our overarching hypothesis relative to the regulation of gene expression in neuronal membrane depolarization, which we believe may also be negatively impacted in ASD. Our hypothesis suggests that the environmental B(a)P exposureinduced downregulation of the neuronal activity-dependent regulation of synapse development is a mechanism that is commonly found in environmental exposure-induced ASD subtypes. We know that postnatal brain development does require input from the environment in order to induce the release of glutamate and thereby promote critical aspects of synaptic maturation. It is during this process of postnatal synaptogenesis that the effects of in utero B(a)P exposure on neural activity are most likely to alter the expression of genes, each with its unique temporal expression profile. Moreover, prenatal exposure for a restricted time period is sufficient to generate long-term changes in Met expression after birth, which in conjunction with other molecular disruptions, are manifested in significant behavioral deficits. B(a)P exposure at 150 lg/kg resulted in reductions in Met expression at PND 10 and 15. A 300 lg/kg exposure resulted in reductions in Met expression at all PNDs examined. Although the lower dose could represent a developmental shift in expression pattern, we believe that the reduction at multiple postnatal time points is consistent with an interpretation that B(a)P exposure at certain prenatal concentrations is sufficient to reduce Met expression throughout postnatal development. Given the role of Met in dendrite and spine growth (Judson et al., 2009), a reduction or shift during the period of peak synapse formation may result in altered maturation of cortical connections. Although it is likely that a number of genes are targeted by B(a)P, the alteration in Met expression would be consistent with its contribution to the disruption of complex behaviors tested here. The paradigm of B(a)P exposure during pregnancy used in this study mimics the kinetics of accumulation in brain tissues measured in other rodent species (Brown et al., 2007; Hood et al., 2000; McCallister et al., 2008; Ramesh et al., 2001), which likely is due to transfer via both transplacental transport and lactation. Extrapolating from the results reported here as well as those from previous experiments in rats (Brown et al., 2007; Hood et al., 2000; McCallister et al., 2008), it appears that prenatal B(a)P exposure can have a robust negative impact on key molecular constituents that are important for the development of excitatory synapses. These B(a)P exposure– induced alterations suggest that G 3 E interactions can be examined directly in mouse models by imposing both genetic and environmental loads that may exacerbate the impact of each individual component on cortical development and cognitive behaviors that are relevant to understanding the G 3 E impact in clinical populations.



The focus on understanding the impact of exposure to a common environmental pollutant on MET is based in part on our initial discovery (Campbell et al., 2006), which was subsequently replicated (Campbell et al., 2009; Jackson et al., 2009; Judson et al., 2009), of MET as an ASD risk gene. Moreover, one of the ASD risk alleles, located in the proximal MET promoter, was shown to alter nuclear protein binding, including that of Sp family members (Campbell et al., 2006). This finding is of significant interest because B(a)P exposure in rats has been shown to affect the temporal expression of neuronal Sp proteins that regulate downstream genes critical to the formation of synapses early in postnatal development (Hood et al., 2000). In vitro studies indicate that Met plays an important role in this process (Tyndall and Walikonis, 2006), which also occurs after the in vivo elimination of Met expression in the neocortex. B(a)P exposure clearly has functional consequences which are manifested by perturbations in the thalamocortical synaptic drive and disruptions in primary sensory functions. The examination of novel object discrimination, described in this study as a measure of prefrontal and limbic circuit integrity, demonstrates a significant negative impact by B(a)P. Thus, PAH exposure in utero has a more pervasive impact on cortical circuits, which could be due in part to the disruption of genes regulated by Sp family members (Liu et al., 2003). We evaluated Cprlox/lox offspring in a behavioral paradigm that focuses on attention, learning and memory impairments, and responses to novelty, all of which are relevant functional domains that exhibit varying degrees of dysfunction in individuals with ASD (Geschwind, 2009). The novel object discrimination task was successfully used in this study to demonstrate alterations in novelty processing in Cprlox/lox offspring as a function of in utero B(a)P exposure. Prenatal exposure to B(a)P was shown to significantly disrupt performance in this task in B(a)P-exposed Cprlox/lox offspring. The results from these studies suggest that the novel object discrimination task is sensitive enough to detect deficits in response to novelty that are reflective of attention and learning and memory impediments (Fig. 5). Collectively, the results presented in the present study strongly suggest that it is highly likely that environmental factors and/or a combination of genetic variants may underlie the heterogeneity of behavioral phenotypes that, in part, determine neurobehavioral pathology. Finally, we have chosen, in this instance, to illustrate the environmental relevance of the highest dose of B(a)P used in the present study (600 mg/kg BW) within the context of neocortical tissue burden during development. As an additional point of reference to the Perera study (Perera et al., 2009), we reference the neocortical tissue burden resulting from a B(a)P aerosol concentration of 100 lg/m3 (Hood et al., 2000). The significance of the developmental neocortical tissue metabolite burden can then be appreciated within the context of the data reported in Perera et al. (2009). In that study, 5-year-old children were exposed in utero to 0.49–34.48 ng/m3 PAHs where greater than half of children ended up in the high PAH exposure group. When these children were tested at 12, 24, and 36 months, children in

the high-exposure group had significantly lower full-scale/verbal IQ scores than the low-PAH exposure group. A very recent report by Wang et al. (2010) has reported the identification of the gene 3 environment interaction between prenatal PAH exposure and a haplotype of CYP1B1 gene (ACCGGC) responsible for the decline in mental development index from that cohort of children. The utility, relevance, and impact of the present study are grounded in the fact that these observations have now been replicated in a transgenic mouse model that is analogous to the human condition. In humans, cytochrome P450-1B1 is the primary extrahepatic PAH bioactivating enzyme in developing neocortical tissue. Our WT Cprlox/lox mouse has proved to be an ideal model to assess the contribution of P450 enzymes to the metabolic activation and disposition of environmental xenobiotics. This is evidenced by the fact that the actual xenobiotic metabolite disposition to neocortex in the present study is well within the order of magnitude of the predicted disposition to the fetus for the environmental concentrations for PAHs that were reported in Perera et al. (2009) and Wang et al. (2010). In conclusion, specific developmental events such as glutamatergic excitatory synapse formation and maturation may be particularly vulnerable to G 3 E effects that impact regulatory and signaling proteins involved in this process. Although we do not suggest that the current study reflects specific defects related to a complex clinical condition such as the ASDs, current molecular, behavioral, and functional imaging data are converging on the concept that the ASDs are a manifestation of altered local and long-distance cortical connectivity (Bill and Geschwind, 2009; Geschwind and Levitt, 2007; Levitt and Campbell, 2009). Also, Met and other related signaling components of this receptor tyrosine kinase pathway have been implicated in both syndromic and idiopathic disorders where the ASDs are diagnosed at a high rate. In combination with risk alleles in key genes, the in utero exposure to PAHs such as B(a)P, which results in both a reduction in absolute levels and the mistiming of peak Met expression, could drive the system toward a pathophysiological threshold that neither genetic risk nor environmental factors could produce individually (Campbell et al., 2010). The present study focused on the neocortex, but given the highly restricted spatial and temporal expression of Met in mouse limbic circuits associated with social-emotional development and cognition (Judson et al., 2009), it is likely that perturbations occur throughout these key circuits, including in the hippocampus. Studies in the immediate future will seek to elucidate the functional changes and specific molecular mechanisms underlying alterations in Met-driven neural activity and plasticity using this G 3 E model.



This work was supported, in part, by National Institutes Health grants S11ES014156, U54NS041071, and


R56ES017448-01A1 to D.B.H., R01ES007462 to X.D., R01CA142845-01A1 to A.R and a grant from the Simons Foundation Autism Research Initiative (P.L., D.B.H.). Institutional grants G12RRO3032, S06GM08037, and T32MH065782 (MMC-VU Alliance for Research Training in Neuroscience).

REFERENCES Akita, H., Takagi, N., Ishihara, N., Takagi, K., Murotomi, K., Funakoshi, H., Matsumoto, K., Nakamura, T., and Takeo, S. (2008). Hepatocyte growth factor improves synaptic localization of the NMDA receptor and intracellular signaling after excitotoxic injury in cultured hippocampal neurons. Exp. Neurol. 210, 83–94. Arlt, W., Walker, E. A., Draper, N., Ivison, H., Ride, J., Hammer, F., Chalder, S., Borucka-Mankiewicz, M., Hauffa, B., Malunowicz, E., et al. (2004). Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363, 2128–2135. Bill, B., and Geschwind, D. (2009). Genetic advances in autism: heterogeneity and convergence on shared pathways. Curr. Opin. Genet. Dev. 19, 271–278. Bolton, J., Trush, M., Penning, T., Dryhurst, G., and Monks, T. (2000). Role of quinones in toxicology. Chem. Res. Toxicol. 13, 135–160. Brown, L., Khousbouei, H., Goodwin, J., Irvin-Wilson, C., Ramesh, A., Sheng, L., McCallister, M., Jiang, G., Aschner, M., and Hood, D. (2007). Down-regulation of early ionotrophic glutamate receptor subunit developmental expression as a mechanism for observed plasticity deficits following gestational exposure to benzo(a)pyrene. Neurotoxicology 28, 965–978. Campbell, D., Buie, T., Winter, H., Bauman, M., Sutcliffe, J., Perrin, J., and Levitt, P. (2009). Distinct genetic risk based on association of MET in families with co-occurring autism and gastrointestinal conditions. Pediatrics 123, 1018–1024. Campbell, D., D#Oronzio, R., Garbett, K., Ebert, P., Mirnics, K., Levitt, P., and Persico, A. (2007). Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann. Neurol. 62, 243–250. Campbell, D., Li, C., Sutcliffe, J., Persico, A., and Levitt, P. (2008). Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res. 1, 159–168. Campbell, D., Sutcliffe, J., Ebert, P., Militerni, R., Bravaccio, C., Trillo, S., Elia, M., Schneider, C., Melmed, R., Sacco, R., et al. (2006). A genetic variant that disrupts MET transcription is associated with autism. Proc. Natl. Acad. Sci. U.S.A 103, 16834–16839. Campbell, D., Warren, D., Sutcliffe, J., Lee, E., and Levitt, P. (2010). Association of MET with social and communication phenotypes in individuals with autism spectrum disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 438–446. Conroy, J., Fang, C., Gu, J., Zeitlin, S., Yang, W., Yang, J., VanAlstine, M., Nalwalk, J., Albrecht, P., Mazurkiewicz, J., et al. (2010). Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nat. Neurosci. 13, 284–286. Fluck, C., Tajima, T., Pandey, A., Arlt, W., Okuhara, K., Verge, C., Jabs, E., Mendonca, B., Fujieda, K., and Miller, W. (2004). Mutant P450 oxidoreductase causes disordered steroidogenesis with and without AntleyBixler syndrome. Nat. Genet. 36, 228–230. Fukami, M., Hasegawa, T., Horikawa, R., Ohashi, T., Nishimura, G., Homma, K., and Ogata, T. (2006). Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr. Res. 59, 276–280.


Fukami, M., Horikawa, R., Nagai, T., Tanaka, T., Naiki, Y., Sato, N., Okuyama, T., Nakai, H., Soneda, S., Tachibana, K., et al. (2005). Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J. Clin. Endocrinol. Metab. 90, 414–426. Geschwind, D. (2009). Advances in autism. Annu. Rev. Med. 60, 367–380. Geschwind, D., and Levitt, P. (2007). Autism spectrum disorders: developmental disconnection syndromes. Curr. Opin. Neurobiol. 17, 103–111. Gu, J., Chen, C., Wei, Y., Fang, C., Xie, F., Kannan, K., Yang, W., Waxman, D., and Ding, X. (2007). A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. J. Pharmacol. Exp. Ther. 321, 9–17. Gu, J., Weng, Y., Zhang, Q., Cui, H., Behr, M., Wu, L., Yang, W., Zhang, L., and Ding, X. (2003). Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J. Biol. Chem. 278, 25895–25901. Gutierrez, H., Dolcet, X., Tolcos, M., and Davies, A. (2004). HGF regulates the development of cortical pyramidal dendrites. Development 131, 3717– 3726. Hood, D., Nayyar, T., Ramesh, A., Greenwood, M., and Inyang, F. (2000). Modulation in the developmental expression profile of Sp1 subsequent to transplacental exposure of fetal rats to desorbed benzo[a]pyrene following maternal inhalation. Inhal. Toxicol. 12, 511–535. Hood, D. B., Woods, L., Brown, L. A., and Ebner, F. F. (2006). Gestational 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin exposure effects on sensory cortex function. Neurotoxicology 27, 1032–1042. Huang, N., Pandey, A., Agrawal, V., Reardon, W., Lapunzina, P., Mowat, D., Jabs, E., Van Vliet, G., Sack, J., Fluck, C., et al. (2005). Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 76, 729–749. Jackson, P., Boccuto, L., Skinner, C., Collins, J., Neri, G., Gurrieri, F., and Schwartz, C. (2009). Further evidence that the rs1858830 C variant in the promoter region of the MET gene is associated with autistic disorder. Autism Res. 2, 232–236. Judson, M., Bergman, M., Campbell, D., Eagleson, K., and Levitt, P. (2009). Dynamic gene and protein expression patterns of the autism-associated met receptor tyrosine kinase in the developing mouse forebrain. J. Comp. Neurol. 513, 511–531. Kerzee, J., and Ramos, K. (2000). Activation of c-Ha-ras by benzo(a)pyrene in vascular smooth muscle cells involves redox stress and aryl hydrocarbon receptor. Mol. Pharmacol. 58, 152–158. Levitt, P. (2003). Structural and functional maturation of the developing primate brain. J. Pediatr. 143, S35–S45. Levitt, P., and Campbell, D. (2009). The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J. Clin. Invest. 119, 747–754. Li, Z., Dong, T., Pro¨schel, C., and Noble, M. (2007). Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. PLoS Biol. 5, e35. Lioy, P. L., Waldman, J. M., Greenberg, A., Harkov, R., and Pietarinen, C. (1988). The Total Human Environmental Exposure Study (THEES) to benzo(a)pyrene: comparison of the inhalation and food pathways. Arch. Environ. Health 43, 304–312. Liu, A., Zhuang, Z., Hoffman, P., and Bai, G. (2003). Functional analysis of the rat N-methyl-D-aspartate receptor 2A promoter: multiple transcription starts points, positive regulation by Sp factors, and translational regulation. J. Biol. Chem. 278, 26423–26434. McCallister, M., Maguire, M., Ramesh, A., Aimin, Q., Liu, S., Khoshbouei, H., Aschner, M., Ebner, F., and Hood, D. (2008). Prenatal exposure to



benzo(a)pyrene impairs later-life cortical neuronal function. Neurotoxicology 29, 846–854.

benzo(alpha)pyrene in F-344 rats following oral administration. Exp. Toxicol. Pathol. 53, 275–290.

Morrow, E., Yoo, S., Flavell, S., Kim, T., Lin, Y., Hill, R., Mukaddes, N., Balkhy, S., Gascon, G., Hashmi, A., et al. (2008). Identifying autism loci and genes by tracing recent shared ancestry. Science 321, 218–223.

Silvers, J., Harrod, S., Mactutu, C., and Booze, R. (2007). Automation of the novel object recognition task for use in adolescent rodents. J. Neurosci. Methods 166, 99–103. Sousa, I., Clark, T., Toma, C., Kobayashi, K., Choma, M., Holt, R., Sykes, N., Lamb, J., Bailey, A., Battaglia, A., et al. (2009). MET and autism susceptibility: family and case-control studies. Eur. J. Hum. Genet. 17, 749–758.

Nakano, M., Takagi, N., Takagi, K., Funakoshi, H., Matsumoto, K., Nakamura, T., and Takeo, S. (2007). Hepatocyte growth factor promotes the number of PSD-95 clusters in young hippocampal neurons. Exp. Neurol. 207, 195–202. Nebert, D., Roe, A., Dieter, M., Solis, W., Yang, Y., and Dalton, T. (2000). Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem. Pharmacol. 59, 65–85. Palmen, S., van Engeland, H., Hof, P., and Schmitz, C. (2004). Neuropathological finding in autism. Brain 127, 2572–2583. Perera, F., Li, Z., Whyatt, R., Hoepner, L., Wang, S., Camann, D., and Rauh, V. (2009). Prenatal airborne polycyclic aromatic hydrocarbon exposure and child IQ at age 5 years. Pediatrics 124, e195–e202. Perera, F., Rauh, V., Whyatt, R., Tsai, W., Tang, D., Diaz, D., Hoepner, L., Barr, D., Tu, Y., Camann, D., et al. (2006). Effect of prenatal exposure to airborne polycyclic aromatic hydrocarbons on neurodevelopment in the first 3 years of life among inner-city children. Environ. Health Perspect. 114, 1287–1292. Powell, E., Campbell, D., Stanwood, G., Davis, C., Noebels, J., and Levitt, P. (2003). Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J. Neurosci. 23, 622–631. Powell, E., Mars, W., and Levitt, P. (2001). Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon. Neuron 30, 79–89. Ramesh, A., Inyang, F., Hood, D., Archibong, A., Knuckles, M., and Nyanda, A. (2001). Metabolism, bioavailability, and toxicokinetics of

Tyndall, S., and Walikonis, R. (2006). The receptor tyrosine kinase Met and its ligand hepatocyte growth factor are clustered at excitatory synapses and can enhance clustering of synaptic proteins. Cell Cycle 5, 1560–1568. Wang, S., Chanock, S., Tang, D., Li, Z., Edwards, S., Jedrychowski, W., and Perera, F. (2010). Effect of gene-environment Interactions on mental development in African American, Dominican, and Caucasian mothers and newborns. Ann. Hum. Genet. 74, 46–56. Wormley, D., Ramesh, A., and Hood, D. (2004). Environmental contaminantmixture effects on CNS development, plasticity, and behavior. Toxicol. Appl. Pharmacol. 197, 49–65. Wortham, M., Czerwinski, M., He, L., Parkinson, A., and Wan, Y. (2007). Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab. Dispos. 35, 1700–1710. Wu, L., Gu, J., Weng, Y., Kluetzman, K., Swiatek, P., Behr, M., Zhang, Q., Zhuo, X., Xie, Q., and Ding, X. (2003). Conditional knockout of the mouse NADPH-cytochrome P450 reductase gene. Genesis 36, 177–181. Wu, R., Zhao, J., Zhai, J., Guo, X., and Guo, W. (2007). Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J. Clin. Psychopharmacol. 27, 374–379.

Suggest Documents